Methylation mediated LINC00261 suppresses pancreatic cancer progression
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA638095 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR11952694_1.fastq.gz | Fastqsanger.gz | |||
| SRR11952694_2.fastq.gz | Fastqsanger.gz | |||
| SRR11952695_1.fastq.gz | Fastqsanger.gz | |||
| SRR11952695_2.fastq.gz | Fastqsanger.gz | |||
| SRR11952696_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 12 |
Similar Datasets
Project description:To the best of our knowledge, this is the first study presenting detailed evidences for the underlying role of LINC00261 in pancreatic cancer both in vitro and in vivo. Also, we thoroughly explored the clinical value of LINC00261 in multicenter cohorts and developed an individualized predictive model of survival. To investigate the potential downstream pathway of LINC00261, we performed RNA-seq using two PANC-1 cell groups: LINC00261 knockdown and control.
2023-06-08 | GSE152012 | GEO
Project description:Background: Due to the limitations of strategies for its early diagnosis and treatment, pancreatic cancer (PC) remains a substantial human health threat. We previously discovered a methylation-mediated lncRNA, LINC00261, which is downregulated in PC tissues. However, the underlying role of LINC00261 in PC remains largely unknown. Methods: Quantitative real-time PCR and in situ hybridization were performed to evaluate the expression levels of LINC00261 in PC, adjacent nontumor and normal pancreas tissues. The clinical significance of LINC00261 was assessed in multicenter PC samples. The functions of LINC00261 in PC were investigated by gain- and loss-of-function assays in vitro and in vivo. Potential downstream pathways and mechanisms were explored via RNA sequencing and bioinformatic analyses. RNA immunoprecipitation and chromatin immunoprecipitation assays were used to validate the underlying mechanisms. Pyrosequencing and targeted demethylation of the LINC00261 promoter were performed to explore the upstream epigenetic mechanisms and therapeutic potential. Results: LINC00261 was significantly downregulated in PC tissues, and its expression was positively associated with the prognosis of PC patients. Phenotypic studies indicated that LINC00261 overexpression significantly suppressed PC cell proliferation, migration and metastasis in vitro and in vivo. c-Myc was identified as a downstream target of LINC00261. LINC00261 repressed c-Myc transcription by physically interacting and binding with the bromo domain of p300/CBP, preventing the recruitment of p300/CBP to the promoter region of c-Myc and decreasing the H3K27Ac level. Moreover, the methylation level of the LINC00261 promoter was high in PC tissues and was correlated with poor prognosis. Targeted demethylation of the LINC00261 promoter inhibited PC progression both in vitro and in vivo. Conclusions: Our findings indicate that methylation-mediated LINC00261 suppresses PC progression by epigenetically repressing c-Myc expression. These findings expand the therapeutic potential of LINC00261, possibly providing evidence to support the development of epigenetic drugs or therapeutic strategies. This research adds further insights into the etiology of PC and indicates that LINC00261 may be a prognostic and therapeutic target in PC.
| S-EPMC7482811 | biostudies-literature
Project description:Accumulating evidence suggests that epithelial-mesenchymal transition (EMT) contributes to metastasis, a major cause of death in patients with colorectal cancer (CRC). MeCP2 (methyl CpG binding protein 2), a key modulator for initiating gene transcription, plays a pivotal role in EMT, but its upstream signaling pathways are poorly understood. We collected 137 colorectal cancer patients’ samples, including tumor tissues (n=137), adjacent normal tissues (n=137) and liver metastases (n=11). Three pairs of colorectal cancer cell lines were sequenced to identify high abundance of lincRNAs in primary tumor tissues. Two independent experiments (electrophoretic mobility shift assay and RNA immunoprecipitation assay) were used to characterize the interaction between LINC00261 and MeCP2. Subsequently, the effects of LINC00261 on phosphorylation of MeCP2 and promotion of the MeCP2-ZEB1 feedback were examined. Consequently long intergenic non-protein coding RNA 261 (LINC00261) was down-regulated in highly metastatic CRC cells and liver metastases from patients with CRC. Down-regulating LINC00261 promoted the expression of EMT markers and increased the invasive and migratory properties of multiple CRC cell lines. Furthermore, knocking down LINC00261 increased colon-derived liver metastasis in an orthotopic CRC model and promoted distant metastatic colonization in a lung metastasis model. Mechanistic studies revealed that LINC00261 interacted with MeCP2 and stabilized it in the nucleus by inhibiting Ser80 phosphorylation Interestingly, ZEB1 could re-modulate MeCP2 expression by binding to the MeCP2 promoter, and they formed a positive feedback loop consequently. In contrast, the lower LINC00261 expression in CRC samples correlated with reduced E-cadherin and membrane β-catenin levels, and was associated with shorter overall survival. Taken together, LINC00261 suppresses EMT and CRC cells’ metastatic potential by negatively regulating the MeCP2-ZEB1 feedback loop; LINC00261’s loss in metastatic tissues may be a potential prognostic marker of aggressive disease.
2024-12-31 | GSE223243 | GEO
Project description:The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice
| PRJNA627490 | ENA
Project description:Lung cancer is the leading cause of cancer-related death in the United States. Long non-coding RNAs (lncRNAs) are a class of regulatory molecules whose role in lung carcinogenesis is poorly understood. In this study, we profiled lncRNA expression in lung adenocarcinoma (LUAD) cell lines, compared their expression to that of purified alveolar epithelial type II cells (the purported cell of origin for LUAD), cross-referenced these with lncRNAs altered in primary human tumors, and interrogated for lncRNA whose expression correlated with patient survival. We identified LINC00261, a lncRNA with unknown function in LUAD, adjacent to the pioneering transcription factor FOXA2. Loss of LINC00261 was observed in multiple tumor types, including liver, breast, and gastric cancer. Reintroduction of LINC00261 into human LUAD cell lines inhibited cell migration and slowed proliferation by inducing a G2/M cell cycle arrest while upregulating DNA damage pathway genes and inducing phosphorylation-mediated activation of components of the DNA damage pathway. FOXA2 was able to induce LINC00261 expression, and the entire locus underwent hypermethylation in LUAD, leading to loss of expression. We have thus identified an epigenetically deregulated lncRNA, whose loss of expression in LUAD promotes the malignant phenotype and blocks activation of the DNA damage machinery, predisposing lung cells to cancer development.
2019-03-01 | GSE110182 | GEO
Project description:Ablation of the gustatory G-protein, GNAT3, in damage and KRAS G12D induced pancreatic transformation enhanced CXCL1 and CXCL2 expression, altered the immunoregulatory gene expression of CXCR2 expressing myeloid-derived suppressor cells, and increased gMDSC presence to promote the progression of metastatic pancreatic ductal adenocarcinoma.
2021-04-21 | GSE149165 | GEO
Project description:FBXO32 drives pancreatic cancer progression
| PRJNA1083527 | ENA
Project description:circNFIB suppresses lymphatic metastasis of pancreatic cancer
| PRJNA562706 | ENA
Project description:Post-translational modifications of malignant transformation and tumor maintenance in pancreatic ductal adenocarcinoma (PDAC) in the context of KRAS signaling remains largely unexplored. Here, we used the KPC mouse model to examine the effect of palmitoylation on pancreatic cancer progression. ZDHHC20, upregulated by KRAS, is abnormally overexpressed and associated with poor prognosis in patients with pancreatic cancer. Dysregulation of ZDHHC20 promotes pancreatic cancer progression in a palmitoylation-dependent manner. ZDHHC20 inhibits lysosomal localization and degradation of YTHDF3 through S-palmitoylation of Cys474, which can result in abnormal accumulation of the oncogenic product MYC and thereby promote the malignant phenotypes of cancer cells. Further, we designed a biologically active YTHDF3-derived peptide to competitively inhibit YTHDF3 palmitoylation mediated by ZDHHC20, which in turn downregulated MYC expression and inhibited the progression of KRAS mutant pancreatic cancer. Thus, these findings highlight the therapeutic potential of targeting the ZDHHC20-YTHDF3-MYC signaling axis in pancreatic cancer.
2024-04-22 | GSE235516 | GEO
Project description:The poor clinical outcome in pancreatic ductal adenocarcinoma (PDA) has been attributed to intrinsic resistance to chemotherapy and a growth-permissive tumor microenvironment. Quiescent pancreatic stellate cells (PSCs) are neuroendocrine, nestin-positive, lipid-accumulating cells whose homologues in the liver are the principal repository of Vitamin A esters. Upon activation, lipid droplets are lost and via transdifferentiation they become the key cell type responsible for driving the severe desmoplasia that characterizes PDA. Despite their critical role in PDA progression and chemoresistance, therapeutic strategies targeting PSCs are lacking. Here we identified the vitamin D receptor (VDR) as a master genomic regulator of PSC activation and function. In vitro we demonstrate that VDR activation reduces expression in PSCs of genes implicated in activation, inflammation, and extracellular matrix production, as well as restoring lipid droplet integrity. In vivo, the VDR ligand calcipotriol enhances the anti-tumor effects of gemcitabine by increasing intratumoral concentration 5-fold, reducing tumor volume to near baseline and lowering metastases by more than 65%. These findings implicate VDR as a master regulator of PSC activation and identify a novel therapeutic approach for the treatment of pancreatic cancer. RNA-Seq analyses was used to characterize cancer-associated changes between pre-activated (3-day culture) and activated (7-day culture) primary mouse PSCs, as well as control and PDA human PSCs. RNA-Seq was also used to assess the impact of VDR activation (DMSO vs calcipotriol) in a human PSC line (MiaPaCa-2), the mouse primary PSCs
2014-10-03 | E-GEOD-43770 | biostudies-arrayexpress